Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

[1] Kastelein JJP(2020)Familial hypercholesterolemia: the most common monogenic disorder in humans J Am Coll Cardiol 75 2567-2569

[2] Reeskamp LF(2014)Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs Curr Atheroscler Rep 16 439-433

[3] Hovingh GK(2018)Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia Atherosclerosis 277 425-367

[4] Abifadel M(2013)Familial hypercholesterolemia and the atherosclerotic disease Korean Circ J 43 363-3490a

[5] Elbitar S(2013)Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 3478-2121

[6] El Khoury P(2016)The p. Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes J Clin Endocrinol Metab 101 2113-424

[7] Alnouri F(2017)Treatment of heterozygous familial hypercholesterolemia in children and adolescents: an unsolved problem Revista Española de Cardiología (Engl Ed) 70 423-3637

[8] Athar M(2017)Lipoprotein apheresis in the treatment of dyslipidemia–the Czech Republic Experience Physiol Res 66 S91-165

[9] Al-Allaf FA(2018)Lipoprotein apheresis and PCSK9-inhibitors. Impact on atherogenic lipoproteins and anti-inflammatory mediators in familial hypercholesterolaemia Curr Pharm Des 24 3634-25

[10] Kim YR(2017)Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis Atheroscler Suppl 30 159-1551

[1] Kastelein JJP(2020)Familial hypercholesterolemia: the most common monogenic disorder in humans J Am Coll Cardiol 75 2567-2569

[2] Reeskamp LF(2014)Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs Curr Atheroscler Rep 16 439-433

[3] Hovingh GK(2018)Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia Atherosclerosis 277 425-367

[4] Abifadel M(2013)Familial hypercholesterolemia and the atherosclerotic disease Korean Circ J 43 363-3490a

[5] Elbitar S(2013)Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 3478-2121

[6] El Khoury P(2016)The p. Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes J Clin Endocrinol Metab 101 2113-424

[7] Alnouri F(2017)Treatment of heterozygous familial hypercholesterolemia in children and adolescents: an unsolved problem Revista Española de Cardiología (Engl Ed) 70 423-3637

[8] Athar M(2017)Lipoprotein apheresis in the treatment of dyslipidemia–the Czech Republic Experience Physiol Res 66 S91-165

[9] Al-Allaf FA(2018)Lipoprotein apheresis and PCSK9-inhibitors. Impact on atherogenic lipoproteins and anti-inflammatory mediators in familial hypercholesterolaemia Curr Pharm Des 24 3634-25

[10] Kim YR(2017)Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis Atheroscler Suppl 30 159-1551